Johnnie Hinton, MD
Nephrology · El Dorado, ARNPI 1215917562
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $998 of the $1,201 with a category attached, or 83.1%. It is spread thinly across 16 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in AR, where the typical reported total is $925.
Across 63 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$215
- Medtronic$175
- Akebia Therapeutics Inc$128
- Amgen$117
- Novo Nordisk$96
- Otsuka America Pharmaceutical, Inc.$96
- plus $374 from 10 others
What the payments were for
- Food & beverage$99883%
- Education$20317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $215 |
| Medtronic | 1 | $175 |
| Akebia Therapeutics Inc | 15 | $128 |
| Amgen(2 entities) | 6 | $117 |
| Novo Nordisk | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 1 | $96 |
| Calliditas Therapeutics US Inc. | 5 | $93 |
| Vifor Pharma, Inc. | 4 | $64 |
| Ardelyx, Inc. | 2 | $53 |
| OPKO Pharmaceuticals, LLC | 3 | $51 |
| Bayer | 2 | $27 |
| Abiomed | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,201 in reported general payments places this provider in the 50th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 49 | $56,792 |
| VelphoroSucroferric Oxyhydroxide | 17 | $49,592 |
| TradjentaLinagliptin | 65 | $39,973 |
| Sevelamer Carbonate | 170 | $26,814 |
| FarxigaDapagliflozin Propanediol | 23 | $19,536 |
| AuryxiaFerric Citrate | 17 | $19,345 |
| JanuviaSitagliptin Phosphate | 37 | $15,077 |
| RenvelaSevelamer Carbonate | 12 | $13,780 |
| EliquisApixaban | 11 | $9,253 |
| Calcium Acetate | 140 | $7,730 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $7,561 |
| Hydralazine Hcl | 507 | $3,642 |
| Bumetanide | 79 | $3,063 |
| Furosemide | 483 | $2,914 |
| Carvedilol | 425 | $2,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $96 | $56,79249 claims |
| Fresenius USA Marketing, Inc.Velphoro | $20 | $49,59217 claims |
| AstraZenecaFarxiga | $215 | $19,53623 claims |
| Akebia Therapeutics IncAuryxia | $128 | $19,34517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 85 nephrology providers in Arkansas.
Other nephrology in El Dorado
- Michael SchonefeldEl Dorado$4K
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
- Mary Shaver-LewisConway$10K
- Clinton EdwardsJonesboro$8K
- Hania Al-ShahrouriFort Smith$8K
- Mashhud MirzaMarion$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.